论文部分内容阅读
目的:研究三甲益肝冲剂抗大鼠实验性肝纤维化作用。方法:采用四氯化碳造成大鼠肝纤维化模型,应用三甲益肝冲剂常量和双倍剂量进行治疗,以大黄虫丸和促肝细胞生长素(pHGF)作对照,放免法测定血清肝纤维化指标,并取肝组织作病理学检查。结果:三甲益肝冲剂治疗组肝纤维化大鼠血浆透明质酸(HA)、Ⅳ型胶原(Ⅳ-C)和层粘连蛋白(LN)分别为380.44±128.14μg/L、25.84±6.24μg/L和51.66±6.93μg/L,较未用药组(分别为560.60±91.06μg/L、39.30±9.67μg/L和32.60±10.14μg/L)明显降低(p<0.05,p<0.01),肝组织纤维化也较轻。双倍剂量组抗肝纤维化作用与常量组疗效相仿,但优于大黄虫丸。结论:三甲益肝冲剂具有显著降低实验大鼠肝纤维化程度的作用。
Objective: To study the effect of Sanjia Yigan Granule on experimental hepatic fibrosis in rats. METHODS: Rat hepatic fibrosis model was induced by carbon tetrachloride, and the treatment was performed with the constant and double doses of Sanjia Yigan Granule. The Dahuangtai Pills and hepatocyte growth factor (pHGF) were used as controls. Radioimmunoassay was used to determine serum hepatic fibrosis. Indicators, and take liver tissue for pathological examination. Results: The levels of HA, IV-C and LN in plasma of rats with liver fibrosis treated with Sanjia Yigan Granule were 380.44±128.14μg/L and 25.84±6.24μg respectively. L and 51.66±6.93μg/L were significantly lower than those in the untreated group (560.60±91.06μg/L, 39.30±9.67μg/L, and 32.60±10.14μg/L, respectively) (p<0.05, p<0.01). Tissue fibrosis is also lighter. The anti-fibrotic effect of the double-dose group was similar to that of the constant group, but superior to that of the Dahuangchong Pill. Conclusion: Sanjia Yigan Granules can significantly reduce the degree of hepatic fibrosis in experimental rats.